Ziopharm’s TCR-T Program at the NCI Continues to Face Delays; MD Anderson Hotspot TCR-T IND Filing on Track for 2021; Q3 2020 Earnings Call Summary
On Thursday, November 5, Ziopharm held their Q3 2020 earnings call (press release / presentation) highlighting that their TCR-T and RPM CAR-T programs remain on track. Of note, management commented that in Q1 2021 they anticipate filing an IND application for their MD Anderson, library TCR-T program. Below, Celltelligence provides insights on Ziopharm’s TCR-T and CAR-T programs, as well as the potential risk associated with further clinical delays.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.